Liu: Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19

Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19

Liu et al., Medicine, doi:10.1097/MD.0000000000024544

Liu et al., Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19, Medicine, doi:10.1097/MD.0000000000024544

Feb 2021 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective PSM analysis of 232 hospitalized patients, 28 treated with aspirin, showing lower mortality with treatment. There was no significant difference in viral clearance.

Important missing comments or errors? Let us know.

risk of death, 75.0% lower, HR 0.25, p = 0.03, treatment 2 of 28 (7.1%), control 11 of 204 (5.4%), adjusted per study, 60 days, KM, PSM.

risk of death, 81.0% lower, HR 0.19, p = 0.02, treatment 1 of 28 (3.6%), control 9 of 204 (4.4%), adjusted per study, 30 days, KM, PSM.

time to viral-, 1.9% higher, relative time 1.02, p = 0.94, treatment 24, control 24, PSM.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Liu et al., 12 Feb 2021, retrospective, propensity score matching, China, peer-reviewed, 8 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Aspirin All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit